The Role of Cannabinoids in Cancer Therapy: Mechanisms, Therapeutic Potential, and Challenges."
DOI:
https://doi.org/10.33687/ricosbiol.02.02.0037Keywords:
Cannabis sativa, cannabinoids,, cannabinoid research rebirth, cancer relief belongings, TRPV1 receptor, GPR55 receptor, cannabinoid-located treatments, apoptosis, angiogenesis, antagonistic-lump effects, endocannabinoid arrangement, THC psychoactivityAbstract
cannabis sativa L. (pot) has been beneficial for a point in time in medicinal and related to sports frameworks, with attraction pharmacological trends attributed to cannabinoids. Amongst almost 108 cannabinoids provided by way of this plant, delta-9-tetrahydrocannabinol (THC) is final forceful and enormous. THC mimics endocannabinoids within the manner that anandamide and 2-arachidonoylglycerol (2-AG), stimulating precise receptors, containing CB1 and CB2. CB1 is especially determined in the crucial fearful system, intervening many cannabinoids' effects, since CB2 became first of all categorized in invulnerable tissues however has due to the truth that existed determined in diverse container kinds. Rising studies focus on the presence of CB1 and CB2 receptors in miscellaneous malignancy cells, sparking interest in the recovery potential of cannabinoids in oncology. Cannabinoids show off antagonistic-tumor characteristics, containing inducing apoptosis, stopping ideas, and impeding angiogenesis, making office work promising bidders for tumor remedy. Moreover, they have comfort advantages, consisting of pain relaxation, fondness stimulation, and the decline of negative agent-induced revulsion and disgorging. No matter those advances, challenges remain in translating preclinical judgments into dispassionate exercises because of limited files from randomized managed troubles and capability affecting the thoughts which will produce wonderful visions outcomes manual THC. This evaluation explores the microscopic manner underlying cannabinoid operation in malignancy, emphasizing restoration uses and barriers. Information on the endocannabinoid plan's act in oncology may additionally moreover open streets for evolving cannabinoid-primarily based situations, weigh efficacy securely to increase affected person outcomes.
Downloads
References
Gaoni, Y. and Mechoulam, R. (1964). Isolation, makeup, and biased combination of an alive constituent of cannabis. Journal of the American Chemical Society, 86, 1646–1647.
Pertwee, R.G. (2008). The various CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9- tetrahydrocannabinol, cannabidiol, and Δ9-tetrahydrocannabivarin. British Journal of Pharmacology, 153, 199–215.
Devane, W.A., Hanus, L., Breuer, A., and others. (1992). Isolation and construction of an intelligence constituent that binds to the cannabinoid receptor. Science, 258, 1946–1949.
Mechoulam, R., Ben-Shabat, S., Hanus, L., and others. (1995). Identification of an inner 2-monoglyceride, present in dog gut, that binds to cannabinoid receptors. Biochemical Pharmacology, 50, 83–90
Sugiura, T., Kondo, S., Sukagawa, A., and others. (1995). 2-Arachidonoylglycerol: an attainable inner-nabinoid receptor ligand in intelligence. Biochemical and Biophysical Research Communication, 215, 89–97.
Pertwee, R.G., Howlett, A.C., Abood, M.E., and others. (2010). International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: further CB1 and CB2. Pharmacological Reviews, 62, 588–631
Matsuda, L.A., Lolait, S.J., Brownstein, M.J., Young, A.C., and Bonner, T.I. (1990). Structure of a cannabinoid receptor and working verbalization of the cloned cDNA. Nature, 346, 561–564.
Munro, S., Thomas, K.L., and Abu-Shaar, M. (1993). Molecular description of a minor receptor for cannabinoids. Nature, 365, 61–65.
Atwood, B.K. and Mackie, K. (2010). CB2: a cannabinoid receptor accompanying a similarity catastrophe. British Journal of Pharmacology, 160, 467–479.
Fernandez-Ruiz, J., Romero, J., Velasco, G., and others. (2007). Cannabinoid CB2 receptor: a new aim for con- troll affecting animate nerve organs container endurance? Trends in Pharmacological Sciences, 28, 39–45
Guzmán, M., Duarte, M.J., Blazquez, C., and others. (2006). A ship dispassionate study of Delta9- tetrahydrocannabinol in inmates accompanying repeating glioblastoma multiforme. British Journal of Cancer, 95, 197–203
Sarfaraz, S., Adhami, V.M., Syed, D.N., Afaq, F., and Mukhtar, H. (2008). Cannabinoids for malignancy treatment: progress and promise. Cancer Research, 68, 339–342.
Katona, I. and Freund, T.F. (2008). Endocannabinoid is a synaptic safe shutoff for electricity in affecting animate nerve organs ailment. Nature Medicine, 14, 923–930.
Pacher, P., Batkai, S., and Kunos, G. (2006). The endocannabinoid order is an arising aim of phar- macotherapy. Pharmacological Reviews, 58, 389–462.
Pertwee, R.G. (2009). Emerging procedures for misusing cannabinoid receptor agonists as cures. British Journal of Pharmacology, 156, 397–411.
Guzmán, M. (2003). Cannabinoids: potential anticancer powers. Nature Reviews Cancer, 3, 745–755.
Velasco, G., Sánchez, C. and Guzmán, M. (2012). Towards the use of cannabinoids as antitumor powers.Nature Reviews Cancer, 12, 436–444
Cudaback, E., Marrs, W., Moeller, T., and Stella, N. (2010). The verbalization level of CB1 and CB2 receptors decides their efficiency at encouraging apoptosis in astrocytomas. PLoS One, 5, e8702.
Hart, S., Fischer, O.M., and Ullrich, A. (2004). Cannabinoids encourage malignancy container conception by way of lump loss determinant beginning-adapting catalyst (TACE/ADAM17)-interfered with transactivation of the epidermal tumor determinant receptor. Cancer Research, 64, 1943–1950
McKallip, R.J., Nagarkatti, M., and Nagarkatti, P.S. (2005). Delta-9-tetrahydrocannabinol improves feelings of malignancy progress and change by the abolition of the antitumor invulnerable reaction. The Journal of Immunology, 174, 3281–3289
Zhu, L.X., Sharma, S., Stolina, M., and others. (2000). Delta-9-tetrahydrocannabinol restricts antitumor immunity by a CB2 receptor-interceded, cytokine-helpless road. The Journal of Immunology, 165, 373–380.
Malfitano, A.M., Ciaglia, E., Gangemi, G., and others. (2011). Update on the endocannabinoid arrangement as an antagonistic-malignancy aim. Expert Opinion on Therapeutic Targets, 15, 297–308.
Carracedo, A., Lorente, M., Egia, A., and others. (2006b). the stress-controlled protein p8 mediates cannabinoid-persuaded apoptosis of cyst containers. Cancer Cell, 9, 301–312
Galve-Roperh, I., Sánchez, C., Cortes, M.L., and others. (2000). Anti-tumoral operation of cannabinoids: involvement of maintained ceramide growth and extracellular signal-controlled kinase incitement. Nature Medicine, 6, 313–319.
Carracedo, A., Gironella, M., Lorente, M., and others. (2006a). Cannabinoids encourage apoptosis of pancreatic cyst containers by way of endoplasmic web stress-connected genes. Cancer Research, 66, 6748–6755.
Salazar, M., Carracedo, A., Salanueva, I.J., and others. (2009). Cannabinoid operation induces autophagy-interfered container obliteration through the provocation of ER stress cruel glioma containers. The Journal of Clinical Investigation, 119, 1359–1372.
Du, K., Herzig, S., Kulkarni, R.N., and Montminy, M. (2003). TRB3: a tribbles homolog that prevents Akt/ PKB incitement by insulin in the liver. Science, 300, 1574–1577.
Vara, D., Salazar, M., Olea-Herrero, N., and others. (2011). Anti-tumoral operation of cannabinoids on hepatocellular malignant growth: part of AMPK-reliant incitement of autophagy. Cell Death and Differentiation, 18, 1099–1111.
Gomez del Pulgar, T., Velasco, G., Sánchez, C., Haro, A., and Guzmán, M. (2002). De novo-combined ceramide is complicated in cannabinoid-persuaded apoptosis. Biochemical Journal, 363, 183–188
Sánchez, C., de Ceballos, M.L., Del Pulgar, T.G., and others. (2001). Inhibition of glioma progresses in vivo by selective incitement of the CB2 cannabinoid receptor. Cancer Research, 61, 5784–5789
Gaoni, Y., and Mechoulam, R. "Isolation, make-up, and Biased mixture of an Alive Constituent of hashish." magazine of the Yankee Chemical Society 86 (1964): 1646–1647.
Pertwee, R. G. "The diverse CB1 and CB2 Receptor Pharmacology of 3 Plant Cannabinoids: Δnine-Tetrahydrocannabinol, Cannabidiol, and Δ9-Tetrahydrocannabivarin." British Journal of Pharmacology 153 (2008): 199–215.
Devane, W. A., Hanus, L., Breuer, A., and so forth. "Isolation and production of an Intelligence Constituent That Binds to the Cannabinoid Receptor." technological know-how 258 (1992): 1946–1949.
Mechoulam, R., Ben-Shabat, S., Hanus, L., and so on. "identity of an internal 2-Monoglyceride, present in dog intestine, That Binds to Cannabinoid Receptors." Biochemical Pharmacology 50 (1995): 83–90.
Sugiura, T., Kondo, S., Sukagawa, A., and so on. "2-Arachidonoylglycerol: A conceivable inner-Cannabinoid Receptor Ligand in Intelligence." Biochemical and Biophysical Research conversation 215 (1995): 89–97
Pertwee, R. G., Howlett, A. C., Abood, M. E., and so on. "worldwide Union of basic and scientific Pharmacology. LXXIX. Cannabinoid Receptors and Their Ligands: in addition CB1 and CB2." Pharmacological evaluations 62 (2010): 588–631.
Matsuda, L. A., Lolait, S. J., Brownstein, M. J., younger, A. C., and Bonner, T. I. "shape of a Cannabinoid Receptor and Operating Verbalization of the Cloned cDNA." Nature 346 (1990): 561–564.
Munro, S., Thomas, k. L., and Abu-Shaar, M. "Molecular Description of a Minor Receptor for Cannabinoids." Nature 365 (1993): 61–65.
Atwood, B. ., and Mackie, ok. "CB2: A Cannabinoid Receptor Accompanying a Similarity Disaster." British Magazine of Pharmacology 160 (2010): 467–479.
Fernandez-Ruiz, J., Romero, J., Velasco, G., and so forth. "Cannabinoid CB2 Receptor: a brand new aim for manipulate Affecting Animate Nerve Organs box patience?" tendencies in Pharmacological Sciences 28 (2007): 39–45.
Guzmán, M., Duarte, M. J., Blazquez, C., and so on. "A ship Dispassionate look at of Delta9-Tetrahydrocannabinol in Inmates Accompanying Repeating Glioblastoma Multiforme." British Journal of Cancer 95 (2006): 197–203.
Sarfaraz, S., Adhami, V. M., Syed, D. N., Afaq, F., and Mukhtar, H. "Cannabinoids for Malignancy treatment: progress and Promise." most cancers studies 68 (2008): 339–342.
Katona, I., and Freund, T. F. "Endocannabinoid as a Synaptic safe Shutoff for energy in Affecting Animate Nerve Organs disorder." Nature Medicine 14 (2008): 923–930.
Pacher, P., Batkai, S., and Kunos, G. "The Endocannabinoid Order Is a bobbing up goal of Pharmacotherapy." Pharmacological opinions 58(2006): 389–462.
Pertwee, R. G. "emerging strategies for Misusing Cannabinoid Receptor Agonists as treatment options." British Magazine of Pharmacology 156 (2009): 397–411.
Guzmán, M. "Cannabinoids: capacity Anticancer Powers." Nature Critiques Most Cancers 3 (2003): 745–756.
Velasco, G., Sánchez, C., and Guzmán, M. "toward the use of Cannabinoids as Antitumor Powers." Nature Critiques Most Cancers 12 (2012): 436–444.
Cudaback, E., Marrs, W., Moeller, T., and Stella, N. "The Verbalization level of CB1 and CB2 Receptors makes a decision their efficiency at Encouraging Apoptosis in Astrocytomas." PLoS One five (2010): e8702.
Hart, S., Fischer, O. M., and Ullrich, A. "Cannabinoids inspire Malignancy box conception oblique Lump Loss Determinant beginning-Adapting Catalyst (TACE/ADAM17)-Interfered with Transactivation of the Epidermal Tumor Determinant Receptor." most cancers studies 64 (2004): 1943–1950.
McKallip, R. J., Nagarkatti, M., and Nagarkatti, P. S. "Delta-9-Tetrahydrocannabinol Improves Feelings of Malignancy Development and Alternate apiece Abolition of the Antitumor Invulnerable Reaction." The magazine of Immunology 174 (2005): 3281–3289.
Zhu, L.X., Sharma, S., Stolina, M., and others. "Delta-9-Tetrahydrocannabinol Restricts Antitumor Immunity by a CB2 Receptor-Interceded, Cytokine-Helpless Road." The Journal of Immunology 165 (2000): 373–380.
Malfitano, A.M., Ciaglia, E., Gangemi, G., and others. "Update on the Endocannabinoid Arrangement as an Antagonistic-Malignancy Aim." Expert Opinion on Therapeutic Targets 15 (2011): 297–308.
Carracedo, A., Lorente, M., Egia, A., and others. "The Stress-Controlled Protein p8 Mediates Cannabinoid-Persuaded Apoptosis of Cyst Containers." Cancer Cell 9 (2006): 301–313.
Galve-Roperh, I., Sánchez, C., Cortes, M.L., and others. "Anti-Tumoral Operation of Cannabinoids: Involvement of Maintained Ceramide Growth and Extracellular Signal-Controlled Kinase Incitement." Nature Medicine 6 (2000): 313–319.
Carracedo, A., Gironella, M., Lorente, M., and others. "Cannabinoids Encourage Apoptosis of Pancreatic Cyst Containers Next to Endoplasmic Web Stress-Connected Genes." Cancer Research 66 (2006): 6748–6755.
Salazar, M., Carracedo, A., Salanueva, I.J., and others. "Cannabinoid Operation Induces Autophagy-Interfered Container Obliteration Through the Provocation of ER Stress Cruel Glioma Containers." The Journal of Clinical Investigation 119 (2009): 1359–1372.
Du, K., Herzig, S., Kulkarni, R.N., and Montminy, M. "TRB3: A Tribbles Homolog That Prevents Akt/PKB Incitement by Insulin in the Liver." Science 300 (2003): 1574–1577.
Vara, D., Salazar, M., Olea-Herrero, N., and others. "Anti-Tumoral Operation of Cannabinoids on Hepatocellular Malignant Growth: Part of AMPK-Reliant Incitement of Autophagy." Cell Death and Differentiation 18 (2011): 1099–1111.
Gomez del Pulgar, T., Velasco, G., Sánchez, C., Haro, A., and Guzmán, M. "De Novo-Combined Ceramide Is Complicated in Cannabinoid-Persuaded Apoptosis." Biochemical Journal 363 (2002): 183–188.
Sánchez, C., de Ceballos, M.L., Del Pulgar, T.G., and others. "Inhibition of Glioma Progresses In Vivo by Selective Incitement of the CB2 Cannabinoid." Nature Medicine 6 (2001): 313–319.
Downloads
Published
Issue
Section
Categories
License
Copyright (c) 2024 Rehan Naqvi, A. Mehdi, Dr. Geetha Kumari Das, Dr Zameer Ahmed, S. Zameer
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/ by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http:// creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
